 Orphazyme AS NASDAQ: ORPH shares are moving higher after providing a regulatory update for arimoclomol in Niemann-Pick disease type C NPC. The Company had a collaborative dialogue with the FDA during the Type A meeting to discuss the Complete Response Letter. 